Immunomodulatory oligonucleotides inhibit neutrophil migration by decreasing the surface expression of interleukin-8 and leukotriene B4 receptors

Immunology

Volumn 144, Issue 2, 2015, Pages 206-217

  Admyre, Charlotte ^a   Axelsson, Lars Göran ^a   von Stein, Oliver ^a   Zargari, Arezou ^a  

^a InDex Pharmaceuticals AB   (Sweden)

Author keywords

Chemotaxis; Inflammation; Neutrophils; Oligonucleotide

Indexed keywords

CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CPG OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 8; LEUKOTRIENE B4 RECEPTOR; TOLL LIKE RECEPTOR 9; CD11B ANTIGEN; IMMUNOLOGIC FACTOR; OLIGONUCLEOTIDE; OVALBUMIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; LEUKOCYTE MIGRATION; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT INFLAMMATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CPG ISLAND; DRUG EFFECTS; FEMALE; GENETICS; IMMUNOLOGY; NEUTROPHIL;

ANIMALS; CHEMOTAXIS, LEUKOCYTE; CPG ISLANDS; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; INFLAMMATION; INTERLEUKIN-8; MACROPHAGE-1 ANTIGEN; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION; NEUTROPHILS; OLIGONUCLEOTIDES; OVALBUMIN; RECEPTORS, INTERLEUKIN-8A; RECEPTORS, INTERLEUKIN-8B; RECEPTORS, LEUKOTRIENE B4; TOLL-LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922496741     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12368     Document Type: Article

References (41)

1. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006; 5:471-84.
2. Wilson HL, Dar A, Napper SK, Marianela Lopez A, Babiuk LA, Mutwiri GK. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides. Int Rev Immunol 2006; 25:183-213.
3. Musch E, Lutfi T, von Stein P, Zargari A, Admyre C, Malek M, Lofberg R, von Stein OD. Topical treatment with the Toll-like receptor agonist DIMS0150 has potential for lasting relief of symptoms in patients with chronic active ulcerative colitis by restoring glucocorticoid sensitivity. Inflamm Bowel Dis 2012; 19:283-92.
4. Hanagata N. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system. Int J Nanomedicine 2012; 7:2181-95.
5. El Kebir D, Jozsef L, Filep JG. Neutrophil recognition of bacterial DNA and Toll-like receptor 9-dependent and -independent regulation of neutrophil function. Arch Immunol Ther Exp (Warsz) 2008; 56:41-53.
6. Hayashi F, Means TK, Luster AD. Toll-like receptors stimulate human neutrophil function. Blood 2003; 102:2660-9.
7. Jozsef L, Khreiss T, Filep JG. CpG motifs in bacterial DNA delay apoptosis of neutrophil granulocytes. FASEB J 2004; 18:1776-8.
8. Fialkow L, Wang Y, Downey GP. Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function. Free Radic Biol Med 2007; 42:153-64.
9. Nasser MW, Raghuwanshi SK, Malloy KM, Gangavarapu P, Shim JY, Rajarathnam K, Richardson RM. CXCR1 and CXCR2 activation and regulation. Role of aspartate 199 of the second extracellular loop of CXCR2 in CXCL8-mediated rapid receptor internalization. J Biol Chem 2007; 282:6906-15.
10. Hammond ME, Lapointe GR, Feucht PH et al. IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors. J Immunol 1995; 155:1428-33.
11. MacDermott RP. Chemokines in the inflammatory bowel diseases. J Clin Immunol 1999; 19:266-72.
12. Frangogiannis NG, Entman ML. Chemokines in myocardial ischemia. Trends Cardiovasc Med 2005; 15:163-9.
13. Pease JE, Sabroe I. The role of interleukin-8 and its receptors in inflammatory lung disease: implications for therapy. Am J Respir Med 2002; 1:19-25.
14. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14:6735-41.
15. Busch-Petersen J. Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases. Curr Top Med Chem 2006; 6:1345-52.
16. Yamagata T, Ichinose M. Agents against cytokine synthesis or receptors. Eur J Pharmacol 2006; 533:289-301.
17. 4 in allergic diseases. Allergol Int 2008; 57:291-8.
18. Kim ND, Chou RC, Seung E, Tager AM, Luster AD. A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis. J Exp Med 2006; 203:829-35.
19. 4 receptor-1 expression by dexamethasone: potential mechanism for enhanced neutrophil survival. J Immunol 2002; 168:3570-6.
20. Kobayashi Y. The role of chemokines in neutrophil biology. Front Biosci 2008; 13:2400-7.
21. 4 receptors. Prostaglandins Leukot Essent Fatty Acids 2003; 69:123-34.
22. Benimetskaya L, Loike JD, Khaled Z et al. Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein. Nat Med 1997; 3:414-20.
23. Samanta AK, Oppenheim JJ, Matsushima K. Interleukin 8 (monocyte-derived neutrophil chemotactic factor) dynamically regulates its own receptor expression on human neutrophils. J Biol Chem 1990; 265:183-9.
24. Khandaker MH, Mitchell G, Xu L et al. Metalloproteinases are involved in lipopolysaccharide- and tumor necrosis factor-α-mediated regulation of CXCR1 and CXCR2 chemokine receptor expression. Blood 1999; 93:2173-85.
25. Feniger-Barish R, Ran M, Zaslaver A, Ben-Baruch A. Differential modes of regulation of cxc chemokine-induced internalization and recycling of human CXCR1 and CXCR2. Cytokine 1999; 11:996-1009.
26. Bartz H, Mendoza Y, Gebker M, Fischborn T, Heeg K, Dalpke A. Poly-guanosine strings improve cellular uptake and stimulatory activity of phosphodiester CpG oligonucleotides in human leukocytes. Vaccine 2004; 23:148-55.
27. Trevani AS, Chorny A, Salamone G, Vermeulen M, Gamberale R, Schettini J, Raiden S, Geffner J. Bacterial DNA activates human neutrophils by a CpG-independent pathway. Eur J Immunol 2003; 33:3164-74.
28. Fuxman Bass JI, Gabelloni ML, Alvarez ME, Vermeulen ME, Russo DM, Zorreguieta A, Geffner JR, Trevani AS. Characterization of bacterial DNA binding to human neutrophil surface. Lab Invest 2008; 88:926-37.
29. Lindau D, Mussard J, Wagner BJ et al. Primary blood neutrophils express a functional cell surface Toll-like receptor 9. Eur J Immunol 2013; 43:2101-13.
30. Picker LJ. Control of lymphocyte homing. Curr Opin Immunol 1994; 6:394-406.
31. Matsumoto K, Hashimoto S, Gon Y, Nakayama T, Horie T. Proinflammatory cytokine-induced and chemical mediator-induced IL-8 expression in human bronchial epithelial cells through p38 mitogen-activated protein kinase-dependent pathway. J Allergy Clin Immunol 1998; 101:825-31.
32. Denault S, April MJ, Stankova J. Transcriptional activation of the interleukin-8 gene by platelet-activating factor in human peripheral blood monocytes. Immunology 1997; 91:297-302.
33. Wozniak A, Betts WH, Murphy GA, Rokicinski M. Interleukin-8 primes human neutrophils for enhanced superoxide anion production. Immunology 1993; 79:608-15.
34. + CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacol Ther 2006; 112:139-49.
35. Qiu Y, Zhu J, Bandi V, Guntupalli KK, Jeffery PK. Bronchial mucosal inflammation and upregulation of CXC chemoattractants and receptors in severe exacerbations of asthma. Thorax 2007; 62:475-82.
36. Papi A, Luppi F, Franco F, Fabbri LM. Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3:245-51.
37. Bielecki B, Mazurek A, Wolinski P, Glabinski A. Treatment of multiple sclerosis with methylprednisolone and mitoxantrone modulates the expression of CXC chemokine receptors in PBMC. J Clin Immunol 2008; 28:122-30.
38. Neu IS, Metzger G, Zschocke J, Zelezny R, Mayatepek E. Leukotrienes in patients with clinically active multiple sclerosis. Acta Neurol Scand 2002; 105:63-6.
39. Bartosik-Psujek H, Stelmasiak Z. The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease. Eur J Neurol 2005; 12:49-54.
40. Hutchinson JH. Leukotriene B4 inhibitors: US2009054466; US2009227603 and US2009253684. Expert Opin Ther Pat 2010; 20:707-14.
41. Chapman RW, Minnicozzi M, Celly CS et al. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther 2007; 322:486-93.